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OUTCOME IN ALLOGENEIC T CELL DEPLETED HAPLO-IDENTICAL
TRANSPLANTATION WITH TCR a/b AND CD 19 DEPLETION IN
PEDIATRIC PATIENTS: A SINGLE-CENTER EXPERIENCE FROM SOUTH
INDIA
Sonamani Ngangbam, Waseem Iqbal, Shobha Badiger, Sharat
Damodar, K.S. Nataraj, B.R. Prathip, Nedun Cherian, Sunil Bhat.
Introduction: One of the methods of T cell depletion has been developed
which provides efﬁcient depletion of a/b T cells from the graft while
retaining large number of effector cells including g/d T cells.
Methods: We reviewed outcomes and immune reconstitution of pediatric
patients who underwent a haplo-identical HSCT with TCR a/b and CD 19
depleted graft.
Results: 19 patients with a median age of 62 months underwent 20
Haplo-HSCT with this technique over two years. Indications of trans-
plant were acute leukemia (ALL 7 and AML 1), thalassemia (n¼4), one
each for osteopetrosis, primary hemophagocytic lymphohistiocytosis,
chronic granulomatous disease, amegakaryocytic thrombocytopenia,
juvenile myelo-monocytic leukemia, sickle cell disease, and unstable
hemoglobin disease. The conditioning regimens were myeloablative
using TBI (n¼9) or chemotherapy (n¼10). The median infused doses of
CD34+ cell, a/b+ T cells, g/d + T cells and CD19+ cells were 16.6106/kg,
0.055106/kg, 9.89106/kg and 0.22106/kg respectively. All except a
salvage transplant achieved neutrophil engraftment, at median of 12
days (range 9 e 20) and platelet engraftment at 11 days (range 7 - 27).
Only one patient experienced graft failure and was retransplanted. Four
patients (21%) developed acute GVHD grade II-IV (three with gut stage 1
and one with skin stage 3). None of the patients developed chronic
GVHD. Viral infection/reactivation was seen with CMV (n¼7), EBV (n¼2)
and adenovirus (n¼1). Five patients died due to relapse (n¼2), sepsis
(n¼1), CMV (n¼1) and adenoviral infection (n¼1). With a median
follow-up of 379 days (range 53 - 756), the probability of event-free
survival for the whole cohort was 73 % (SE 12.1). Immune reconstitution
kinetics showed a robust NK cells recovery in the immediate post-
transplant period.
Conclusions: Haplo-identical transplantation using TCR a/b and CD 19
depleted graft may be associated with reduced risk of acute GVHD. In-
fectious complications especially viral infections are common.
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REDUCED TOXICITY AND EXCELLENT OUTCOMES USING A
TREOSULPHAN BASED CONDITIONING REGIMEN AND UNRELATED
HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH
THALASSAEMIA MAJOR
V.S. Venkateswaran, Ramya Uppuluri, S. Divya, J. Dhaarani, V.
Lakshmanan, Menaga, Revathi Raj. Department of Paediatric
Haematology, Oncology and Blood and Marrow Transplantation, Apollo
Speciality Hospital, Chennai, India
Aim: Thalassaemia major affects 10,000 new babies each year in our
country and these children need to be treated with lifelong monthly
blood transfusion and chelation. Haematopoietic stem cell trans-
plantation is the only curative option for these patients. Unfortunately,
only 35% of our patients have a fully matched family donor. With
increasing awareness and access to donor registries with Indian donor
databases, we have been able to ﬁnd optimally matched donors for our
patients. We have analysed the outcome in children with thalassaemia
major who underwent fully matched unrelated haematopoietic stem cell
transplantation with a treosulfan based conditioning regimen at our
centre.
Patients and methods: We conducted a retrospective study of children
with thalassaemia major who underwent fully matched unrelated bone
marrow transplantation in our centre from 2012 to 2016. The match level
accepted was 10/10 for an adult donor and 8/8 for cord blood stem cells.
Acute events like sepsis graft versus host disease, bleeding and sinusoidal
obstruction syndrome and chronic complications like graft versus hostdisease, graft rejection and mortality were recorded. The children were
treated using a uniform protocol of thiotepa, treosulphan, ﬂudarabine and
antithymocyte globulin with tacrolimus as the drug of choice for
immunosuppression.
Results: A total of 21 children have undergone an unrelated fully matched
haematopoietic stem cell transplantation at our centre using cord blood
as a source in 3 children and adult peripheral blood stem cells in 18
children. Twelve were boys and 9 were girls ranging from 1 year to 14
years of age. There was one death due to gram negative sepsis in a child
undergoing cord blood stem cell transplantation resulting in a mortality
rate of 4.7%. Acute skin graft versus host disease (GVHD) occurred in 30%
children, acute gut GVHD in 35% and mild chronic skin and mouth GVHD
in 45% patients. Posterior reversible encephalopathy syndrome due to a
combination of steroids and tacrolimus was seen in 24% children and
steroid induced diabetes in 5% children. Reactivation of cytomegalovirus
was seen in 38% children and routine CMV PCR monitoring and pre-
emptive therapy helped prevent CMV disease in these children. Rare
manifestation of GVHD in the form of immune cytopenia was seen in 20%
children. There were no graft rejection or sinusoidal obstruction syn-
drome seen.
Conclusion: Unrelated donor transplantation is now a realistic therapy for
children with thalassemia major in India. Treosulfan based conditioning
therapy, optimal donor selection and early transplantation before the
onset of iron overload has resulted in outcomes on par with sibling donor
transplantation with over 90% cure rates. We need to create greater
awareness to increase our donor databases and we also need to work with
NGOs and government to expand access to care to cover the cost of 25
lakhs needed for each of these procedures.
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PEDIATRIC EWING SARCOMA: EXPERIENCE FROM TATA MEDICAL
CENTER, KOLKATA
Debjani Ghosh 1, Anirban Das 1, Shekhar Krishnan 1, Rimpa Basu
Achari 2, Gautam Biswas 3, Divya Midhya 4, Saugata Sen 5, Vaskar
Saha 1, Arpita Bhattacharyya 1. 1Department of Pediatric Hematology &
Oncology; 2Radiation Oncology; 3 Plastic & Reconstructive Surgery;
4Histopathology; 5Radiology, Tata Medical Center, Kolkata, India
Aim: Survival in childrenwith localized Ewing sarcoma is ~70% inWestern
studies. Our aim was to evaluate the clinical proﬁle and outcome in a new
tertiary non-proﬁt cancer hospital in Eastern India.
Material & Methods: Children (<18-years) with Ewing's sarcoma were
enrolled between January 2011 and May 2016. Information was
collected retrospectively from hospital records. Demographic proﬁle,
clinical features, pathology, treatment and outcome were analyzed.
Kaplan-Meier method was used for survival analysis. Multivariate lo-
gistic regression analysis was used to evaluate risk factors for relapse/
progression.
Results: Thirty-four children were enrolled. Median age was 10.5-years
(Range:1.4e16.9). Male:female was 2:1. Presenting complaints included:
swelling (21;61%), pain (19;55%), restriction of movement (7;20%), fever
(6;17%), neuropathy (6;17%), and, respiratory distress (1).
Diagnosis was conﬁrmed by histopathology in all. EWSR1 gene rear-
rangement was performed in 7 patients and was positive in 6. Disease in
localized in 21 (70%) and metastatic in 9 (30%); data was missing in 4
patients. Six (20%) had presented with relapse/refractory disease. Origin
was skeletal in 26 (76%) and extra-skeletal in 8 (23%). Nineteen (55%)
had axial tumor, while 15 (44%) had non-axial disease. Sites of axial
disease included the pelvis (7;36%), spine and vertebra (5;26%), chest-
wall (5;26%), abdomen (1;0.05%), and, head and neck (1;0.05%). Sites of
non-axial disease included the upper extremity (7;46%) and lower ex-
tremity (8;53%). The most frequently involved bone was the tibia.
Metastatic sites included: isolated lung (4;44%), isolated bone (2;22%),
lymph nodes (2;22%), disseminated disease (lung, bone, bone marrow:
1;0.1%).
Twenty-seven (79%) children received treatment, including 4 who
received palliative chemotherapy. There was heterogeneity in the
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(4;17%).
Multimodal treatment was used in 23 (85%): chemotherapy and radiation
in 8 (34%), chemotherapy and surgery in 5 (21%), chemotherapy, surgery
and radiation in 10 (43%). Nine patients with non-axial disease and 5
patients with axial disease had surgery (p¼0.03). Median follow-up for
the treated patients was 27.5-months (Range:1-90).Out of 23 children
who received curative treatment-11(47%) were alive &well, 5 (21%) were
on treatment, 2 (0.08%) abandoned treatment & 4 (0.17%) had relapse/
refractory disease; one (0.04%) patient died from treatment related
toxicity. Five-year overall survival and event-free survival were 40% &
52%, respectively. Axial location (p¼0.27), metastatic disease (p¼0.74),
and lack of surgery (p¼0.34) were not statistically predictive of relapse/
progression, probably due to low numbers of patient and limited duration
of follow up.
Conclusions: In spite of a similar clinical proﬁle and disease stage, the
outcome of Ewings sarcoma in our patients simulates that reported in
Indian studies, however lags behind Western statistics. Reducing aban-
donment by tracking defaulters and providing support, using a uniform
protocol, and improving supportive care, were identiﬁed as plausible steps
to improve outcomes.ST-1_V1.2
CLINICAL EXPERIENCE AND OUTCOME OF HEPATOBLASTOMA IN
CHILDREN: A 9-YEAR RETROSPECTIVE STUDY
Sanjeev Khera, Amita Trehan, K.L.N. Rao, Deepak Bansal, Nandita
Kakkar, Radhika Srinivasan. PGIMER, Chandigarh, India
Background: Hepatoblastoma (HBL) is the most common primary liver
tumor in children. Metastatic disease at presentation, alphafetoprotein
(AFP) less than 100 ng/ml, PRETEXT IV, undifferentiated histology are usual
poor prognostic markers. Neoadjuvant chemotherapy with surgical
resection has led to increased survival of these patients
Aim: This single centre study assesses the outcome and the factors
affecting prognos is of children treated as per guidelines of SIOPEL3 in a
low middle income country (LMIC).
Materials & Methods: Forty children with HBL treated as per protocol
from Jan 2007 to Dec 2015 were analyzed. The diagnosis was established
by imaging, AFP and histology/cytology.
Results: 27 boys & 13 girls; median age 12 months (2-120) with a mean
symptom diagnosis interval (SDI) of 5.3 weeks (1-24) were diagnosed.
Multifocal involvement was seen in 7/40. Median AFP at diagnosis: 16500
ng/ml (3-406198). 2 had AFP less than 100 ng/ml. Mean platelet count at
diagnosis was 701375/cmm (95% CI 595510.80 to 807239.20).7 (17.5%)
had metastatic disease (6 lungs; 1 adrenal). PRETEXT: I-IV: 6, 13, 11 & 9.
Nineteen: high risk (HR) disease (7 with SDI more than 8 weeks) 13/40
defaulted/refused therapy. All cases received neoadjuvant chemotherapy.
3 deaths occurred prior to surgery. 25 underwent surgery; complete
resection (CR): 18/25 [14 : well; 3 relapsed, 1 died]. 7 cases subtotal
resection : 2 : well, 4 had persistant disease and 1 death.2/3 childrenwho
received salvage chemotherapy with Docetaxel had no response. HR
patients had a poorer outcome (p¼.012), more multifocal disease
(p¼.0395) and signiﬁcantly lower CR (p¼.0016) as compared to standard
risk patients. On comparing well Vs relapsed/residual disease cases;
there was no difference in AFP levels, volume reduction after neo-
adjuvant therapy, metastasis, & histopathology (p¼ns). Relapsed/resid-
ual disease was signiﬁcantly higher in those with higher mean age (24
mth Vs 12 mth); PRETEXT IV & multifocal disease (p¼0.02 & 0.04).
16 of 27 patients are presently well; median follow up being 48.3 months
(7-101).
Conclusion: 59 % (16/27) of cases whowere treated are well. 86%of SR HBL
had good outcome. Higher age at presentation, multifocality and high
PRETEXT was associated with poor outcome. HR patients had a longer SDI.
Docetaxel as a salvage therapy was not effective. Liver transplant, not
available at our centre, would have helped the children with incomplete
resection. Delayed referral and diagnosis remains a problem in LMIC's as
evident by greater SDI in those with HR disease.ST-1_V1.3
MULTIDISCIPLINARY MANAGEMENT OF HEPATOBLASTOMA WITH
INCORPORATION OF LIVER TRANSPLANTATION IN CHILDREN
Vimal Kumar 2, Naresh Shanmugam1, Julius Xavier Scott 2, Mukul
Vij 3, Priya Ramachandran 4, Gomathy Narasimhan 4, Mettu Srinivas
Reddy 4, Venugopal 4, Deenadayalan Munirathnam 3, Chayarani
Kelgeri 1, Karthick Sundaram1, Mohamed Rela 1. 1Department of Pediatric
Gastroenterology, Hepatology and Nutrition, Global Health City, Chennai,
India; 2Department of Pediatric Hematology and Oncology, Global Health
City, Chennai, India; 3Department of Histopathology, Global Health City,
Chennai, India; 4 Institute of Liver diseases & transplantation, Global Health
City, Chennai, India
Abstract
Background: Advances in chemotherapy, liver resection techniques and
pediatric liver transplantation have vastly improved survival in children
with hepatoblastoma (HB). These are best managed by a multidisciplinary
team in a setting where all treatment options are available. Until recently
this was difﬁcult to achieve in India.
Methods: Review of all children (< 16yrs) with HB treated in a pediatric
liver surgery & transplantation unit between Jan 2011 and July 2016. Data
regarding the clinical presentation, pre-operative management, surgical
treatment, postoperative course and outcomes was extracted from a pro-
spectively managed database.
Results: Thirty children were treated for HB during the study period.
Nine children were PRETEXT 4, 7 were PRETEXT 3, 13 were PRETEXT 2
and one was PRETEXT 1. All children received neoadjuvant chemo-
therapy before surgery followed by adjuvant chemotherapy. Nineteen
children had complete resection, while six underwent primary living
donor liver transplantation. There were 6 mortalities including 5 chil-
dren who poorly responded to chemotherapy with progressive tumor
extension. At a median follow-up of 30 months, two children who un-
derwent resection and one child who underwent liver transplant had
disease recurrence.
Conclusion: Improved outcomes can be achieved in childrenwith HB even
in countries with limited resources when they are managed by multidis-
ciplinary teams with expertise in pediatric oncology, liver resection and
liver transplantation.ST-1_V1.4
CLINICOPATHOLOGICAL PROFILE OF PEDIATRIC MEDULLOBLASTOMA
Rikki R. John 1, Leenu Joseph 1, Ari G. Chacko 2, Ranjit Moorthy 2,
Magesh P 3, Geeta Chacko 3, Leni G. Mathew1. 1 Pediatric Hematology/
Oncology, Christian Medical College, Vellore, India; 2Neurosurgery,
Christian Medical College, Vellore, India; 3Neuropathology, Christian
Medical College, Vellore, India
Introduction: Medulloblastoma is the second most common primary
malignant brain tumour in children. We present the clinic-pathological
proﬁle of children seen in a pediatric hematology/Oncology unit over a
ten-year period.
Method: Clinical and laboratory data of children with medulloblastoma
who attended the pediatric hematology/oncology unit of CMC, Vellore
from 2004 to 2014 were retrieved from the medical records and reviewed.
Results: 76 children, 49 boys and 27 girls, with mean age at presentation
8.5±3.45 years. 7 were < 3 years and 22 were >10years. Headache (86%)
vomiting (79%) and ataxia (58%) were the common symptoms. The mean
duration from onset of symptoms to diagnosis was 2.7 ±2.2 months with
78% diagnosed within 3 months. All children presented to the neurosur-
gical team at ﬁrst visit. 30% required emergency CSF diversion procedure.
All children underwent upfront surgical excision; 30 had residual tumour
>1.5cm2. Risk stratiﬁcation based on age at presentation, volume of re-
sidual tumour and presence of metastatic disease, showed 43/76 to be in
the high risk category.
Histological classiﬁcation showed the following: classic 22 (37%), desmo-
plastic 19 (33%), medulloblastoma with extensive nodularity9 (16%), large
